Med­corp has record­ed im­proved af­ter-tax in­come for the first quar­ter of 2026.

In the com­pa­ny's unau­dit­ed in­ter­im fi­nan­cial state­ments for the quar­ter end­ed March 31, 2026, the com­pa­ny re­port­ed to­tal com­pre­hen­sive in­come of $10.88 mil­lion, an im­prove­ment over the $9.5 mil­lion record­ed for the same pe­ri­od in 2025.

In a state­ment, Med­corp ex­ec­u­tive chair Dr Di­nesh Mor al­so not­ed that prof­it be­fore tax for the quar­ter al­so stood at $10.88 mil­lion but this was less com­pared to the $11.12 mil­lion prof­it be­fore tax fig­ure re­port­ed last year for the quar­ter.

Mor said, "While mar­gin­al­ly low­er, the re­sult demon­strates the con­tin­ued strength and re­silience of the com­pa­ny's earn­ings base."

He added, "To­tal rev­enue for the pe­ri­od amount­ed to $33.25 mil­lion, com­pared to $32.41 mil­lion in the cor­re­spond­ing pe­ri­od of 2025, rep­re­sent­ing an in­crease of $840,000 (3 per cent). This growth re­flects the con­tin­ued sta­bil­i­ty and con­sis­ten­cy of the com­pa­ny's core busi­ness ac­tiv­i­ties. Gross prof­it im­proved to $21.88 mil­lion, com­pared to $21.70 mil­lion in the pri­or pe­ri­od, in­di­cat­ing sta­ble mar­gins de­spite a dy­nam­ic cost en­vi­ron­ment. The com­pa­ny main­tained op­er­a­tional dis­ci­pline, with ad­min­is­tra­tive ex­pens­es in­creas­ing mod­er­ate­ly in line with busi­ness re­quire­ments."

He con­tin­ued, "Med­corp re­mains well-po­si­tioned to sus­tain its growth tra­jec­to­ry, sup­port­ed by a strong as­set base, dis­ci­plined cost man­age­ment and con­sis­tent prof­itabil­i­ty. The board and man­age­ment are con­fi­dent that the com­pa­ny's strat­e­gy will con­tin­ue to de­liv­er val­ue to share­hold­ers while main­tain­ing long-term fi­nan­cial sta­bil­i­ty."

Med­corp is an op­er­a­tor of pri­vate health­care fa­cil­i­ties lo­cat­ed in north-west Trinidad, in­clud­ing St Clair Med­ical Cen­tre; Good­health Med­ical Cen­tre; the Bri­an Lara Can­cer Treat­ment Cen­tre; and Doc­tors Ra­di­ol­o­gy Cen­tre.

It was list­ed on the Trinidad and To­ba­go Stock Ex­change's SME mar­ket in Ju­ly last year af­ter an Ini­tial Pub­lic Of­fer­ing which was over­sub­scribed.

In a no­tice post­ed to the TTSE, the Com­pa­ny ad­vised that Mr. Ger­rard Lee - In­niss re­signed as an in­de­pen­dent di­rec­tor at Med­corp ef­fec­tive May 11, 2026.